Temperature-Sensitive RNA Antigens for Localized Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer immunotherapies struggle to induce potent cellular immune responses against tumor-associated and tumor-specific antigens, as current methods often express these antigens in both tumor and normal cells, limiting their effectiveness.
Innovation Solution
A temperature-controllable, self-replicating RNA (c-srRNA) platform is used to express tumor-associated and tumor-specific antigens, which are designed to be functional at skin temperature (30-35°C) and inactive at body temperature (37°C), eliminating systemic spread and enhancing intradermal delivery efficacy without the need for adjuvants or lipid nanoparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antigens are expressed using conventional methods, then immune response is induced, but antigens are expressed in both tumor and normal cells reducing effectiveness
Solution Approach 1:
The patent applies local quality by creating RNA molecules with temperature-specific functionality - the RNA is functional at skin temperature (30-35°C) for intradermal delivery but inactive at body temperature (37°C), thereby localizing antigen expression to the injection site and preventing systemic spread to normal cells
Solution Approach 2:
The patent utilizes parameter changes by modifying the temperature sensitivity of the RNA molecule through specific nucleotide substitutions in the replicase gene, allowing the RNA to be active only within a specific temperature range (30-35°C) and inactive outside this range, thus controlling where and when antigen expression occurs
2Reliability
If temperature-controllable c-srRNA is used for intradermal delivery, then systemic spread is eliminated and efficacy is enhanced, but device complexity increases
Solution Approach 1:
The patent applies self-service by designing the RNA molecule to automatically respond to temperature conditions - the temperature-sensitive replicase automatically prevents replication at body temperature without requiring external control mechanisms, simplifying the overall system while maintaining complexity only at the molecular level
3Ease of manufacture
If conventional immunotherapies are used, then antigen expression is achieved, but adjuvants and lipid nanoparticles are required increasing complexity
Solution Approach 1:
The patent applies taking out by removing the need for adjuvants and lipid nanoparticles from the formulation - the temperature-controllable c-srRNA itself provides the necessary control and delivery functionality, eliminating auxiliary components and simplifying the overall therapeutic formulation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The c-srRNA platform induces robust cellular immune responses against cancer cells, effectively suppressing tumor growth while minimizing systemic distribution and avoiding reactogenicity, thus providing a safer and more potent immunotherapy approach.
Implementation Method 1
A temperature-controllable, self-replicating RNA (c-srRNA) platform is used to express tumor-associated and tumor-specific antigens, which are designed to be functional at skin temperature (30-35°C) and inactive at body temperature (37°C)
Data Source
AI summary
The present disclosure relates to expression of fusion proteins for cancer immunotherapy in a mammalian subject, such as a human subject. In particular, the present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding a plurality of tumor-associated and/or tumor-specific antigens.